153 related articles for article (PubMed ID: 6254933)
1. [The diagnosis of nasopharyngeal carcinoma (author's transl)].
Arnold W; Nakazima A; Wang YB; Vosteen KH; Brunner H; Göbel U
HNO; 1980 Aug; 28(8):247-60. PubMed ID: 6254933
[TBL] [Abstract][Full Text] [Related]
2. Malaria antibody levels in patients with nasopharyngeal carcinoma.
Yadav M; Prasad U
Southeast Asian J Trop Med Public Health; 1984 Jun; 15(2):234-7. PubMed ID: 6095462
[TBL] [Abstract][Full Text] [Related]
3. Nasopharyngeal carcinoma and Epstein-Barr virus--associated serologic markers.
Tam JS; Murray HG
Ear Nose Throat J; 1990 Apr; 69(4):261-7. PubMed ID: 2161732
[TBL] [Abstract][Full Text] [Related]
4. [Epstein-Barr virus--a clinically relevant feature of nasopharyngeal carcinoma? (author's transl)].
Wilmes E; Wolf H; Deinhardt F; Naumann HH
Laryngol Rhinol Otol (Stuttg); 1981 Jan; 60(1):4-6. PubMed ID: 6261051
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr virus-related lymphocyte stimulation inhibitor: a possible prognostic tool for undifferentiated nasopharyngeal carcinoma.
Kamaraju LS; Levine PH; Sundar SK; Ablashi DV; Faggioni A; Armstrong GR; Bertram G; Krueger GR
J Natl Cancer Inst; 1983 Apr; 70(4):643-7. PubMed ID: 6300502
[TBL] [Abstract][Full Text] [Related]
6. Nasopharyngeal carcinoma and Epstein-Barr virus. II. Clinical course and the anti-VCA antibody.
Lynn T; Tu S; Hirayama T; Kawamura A
Jpn J Exp Med; 1973 Apr; 43(2):135-44. PubMed ID: 4352112
[No Abstract] [Full Text] [Related]
7. Analyses of the prognostic significance of the Epstein-Barr virus transactivator ZEBRA protein and diagnostic value of its two synthetic peptides in nasopharyngeal carcinoma.
Dardari R; Menezes J; Drouet E; Joab I; Benider A; Bakkali H; Kanouni L; Jouhadi H; Benjaafar N; El Gueddari B; Hassar M; Khyatti M
J Clin Virol; 2008 Feb; 41(2):96-103. PubMed ID: 18024156
[TBL] [Abstract][Full Text] [Related]
8. The reliability of IgA antibody to Epstein-Barr virus (EBV) capsid antigen as a test for the diagnosis of nasopharyngeal carcinoma (NPC).
Levine PH; Pearson GR; Armstrong M; Bengali Z; Berenberg J; Easton J; Goepfert H; Henle G; Henle W; Heffner D; Huang A; Hyams VJ; Lanier A; Neel HB; Pilch B; Pointek N; Taylor W; Terebelo H; Weiland L
Cancer Detect Prev; 1981; 4(1-4):307-12. PubMed ID: 6299561
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma (NPC).
Liu MT; Yeh CY
Radiat Med; 1998; 16(2):113-7. PubMed ID: 9650898
[TBL] [Abstract][Full Text] [Related]
10. Loss of heterozygosity and its correlation with clinical outcome and Epstein-Barr virus infection in nasopharyngeal carcinoma.
Shao JY; Huang XM; Yu XJ; Huang LX; Wu QL; Xia JC; Wang HY; Feng QS; Ren ZF; Ernberg I; Hu LF; Zeng YX
Anticancer Res; 2001; 21(4B):3021-9. PubMed ID: 11712805
[TBL] [Abstract][Full Text] [Related]
11. [Carcinomas of the nasopharynx. Relationship between histological type and anti-Epstein-Barr virus serology (author's transl)].
Micheau C; de The G; Orofiamma B; Schwaab G; Brugere J; Tursz T; Sancho-Garnier H; Cachin Y
Nouv Presse Med; 1980 Jan; 9(1):21-4. PubMed ID: 6243770
[TBL] [Abstract][Full Text] [Related]
12. Comparison of three different serological techniques for primary diagnosis and monitoring of nasopharyngeal carcinoma in two age groups from Tunisia.
Karray H; Ayadi W; Fki L; Hammami A; Daoud J; Drira MM; Frikha M; Jlidi R; Middeldorp JM
J Med Virol; 2005 Apr; 75(4):593-602. PubMed ID: 15714486
[TBL] [Abstract][Full Text] [Related]
13. Epstein Barr virus (EBV) antibodies in the diagnosis of NPC--comparison between IFA and two commercial ELISA kits.
Chan SH; Soo MY; Gan YY; Fones-Tan A; Sim PS; Kaur A; Chew CT
Singapore Med J; 1998 Jun; 39(6):263-5. PubMed ID: 9803815
[TBL] [Abstract][Full Text] [Related]
14. Nasopharyngeal carcinoma and Epstein-Barr virus. I. Factors related to the anti-VCA antibody.
Lynn T; Tu S; Hirayama T; Kawamura A
Jpn J Exp Med; 1973 Apr; 43(2):121-33. PubMed ID: 4352111
[No Abstract] [Full Text] [Related]
15. [Occult nasopharyngeal carcinoma (author's transl)].
Schmauz R; Hoppe W; zur Hausen H
Dtsch Med Wochenschr; 1975 Dec; 100(49):2527-9. PubMed ID: 172307
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma.
Twu CW; Wang WY; Liang WM; Jan JS; Jiang RS; Chao J; Jin YT; Lin JC
Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):130-7. PubMed ID: 16979842
[TBL] [Abstract][Full Text] [Related]
17. Nasopharyngeal carcinoma and Epstein-Barr virus. III. The detection of anti-nuclear antibodies.
Lynn TC; Hsu MM; Hsieh T; Tu SM; Hamajima K
Jpn J Exp Med; 1976 Oct; 46(5):289-95. PubMed ID: 189106
[TBL] [Abstract][Full Text] [Related]
18. [The usefulness of serum antibody to Epstein-Barr virus-specific DNAase (EDAb) in early detection of nasopharyngeal carcinoma].
Huang D
Zhonghua Zhong Liu Za Zhi; 1993 Jul; 15(4):289-91. PubMed ID: 8174467
[TBL] [Abstract][Full Text] [Related]
19. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
[TBL] [Abstract][Full Text] [Related]
20. Outcome of patients with positive Epstein-Barr virus serologic status in the absence of nasopharyngeal carcinoma in Hong Kong.
Lo S; Ho WK; Wei WI
Arch Otolaryngol Head Neck Surg; 2004 Jun; 130(6):770-2. PubMed ID: 15210561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
